R&D

Designing the Next Generation of Vaccines

Designing the Next Generation of Vaccines

Written by on November 13, 2014 in R&D with 0 Comments

Sylvie Bertholet, PhD Head In vivo Immunology, Novartis Vaccines & Diagnostics joined us last year at the World Vaccine Congress Europe to present on ‘Designing the Next Generation of Vaccines’ Download this presentation now to find out more about: Designing the Next Generation Vaccines What is a self-amplifying mRNA (replicon)? How does SAM work? A […]

Continue Reading

Polio Set To get The Nanopatch Treatment from Vaxxas

Polio Set To get The Nanopatch Treatment from Vaxxas

Written by on September 22, 2014 in R&D with 0 Comments

Vaxxas announces a WHO funded project to evaluate the delivery of polio vaccine using Nanopatch Australian company Vaxxas last week announced the initiation of a research project designed to evaluate the commercialisation prospects of Nanopatch, their microneedle platform for the delivery of polio vaccine. Vaxxas’ Nanopatch consists of a 1cm2 square of silicon with around 20,000 […]

Continue Reading

Therapeutic

The Problem with Cancer Vaccines

The Problem with Cancer Vaccines

You can’t treat a heterogeneous disease with a homogeneous treatment. That was the takeaway message from Vaccinogen’s founder at the World Vaccines Congress Europe Vaccine Nation caught up with Michael Hanna, the founder of Vaccinogen and creator of autologous patient-specific tumour cell vaccine OncoVAX, to discuss why there have been so many high-profile cancer vaccine failures and […]

Continue Reading

Inovio Presents Phase II Clinical Efficacy Data at the 15th World Vaccine Congress

Inovio Presents Phase II Clinical Efficacy Data at the 15th World Vaccine Congress

Written by on September 15, 2014 in Prophylactic Vaccines, R&D, Therapeutic Vaccines, Vaccines Live with 1 Comment

With the 15th World Vaccine Congress on 13 – 15 October in Brussels is just next month I conducted an interview to one of our key speakers, Dr. Niranjan Y. Sardesai (COO, Inovio Pharmaceuticals, Inc.) to give you further insight into his new exciting clinical data and current challenges in developing cancer DNA vaccines.  Dr. […]

Continue Reading

Prophylactic

Sanofi’s Dengue Vaccine To Market in 2015

Sanofi’s Dengue Vaccine To Market in 2015

Written by on November 4, 2014 in Emerging Markets, Prophylactic Vaccines with 3 Comments

Sanofi Pasteur announces a successfull phase III trial in Latin America and plans to enter the market in 2015 The vaccines division of Sanofi  has published the results of their second phase III trial of their dengue vaccine candidate. The study, published in The New England Journal of Medicine, looked at the efficacy of the […]

Continue Reading

Johnson & Johnson To Fast Track Ebola Vaccine Trials

Johnson & Johnson To Fast Track Ebola Vaccine Trials

Written by on September 5, 2014 in Featured on App, News, Prophylactic Vaccines with 0 Comments

Amongst the flurry of efforts to combat the West African Ebola outbreak, Johnson & Johnson is trying its hand at developing a vaccine Johnson & Johnson can be counted amongst the ranks of yet another pharmaceutical company that has joined the race to develop an Ebola vaccine. Thus far, the most advanced vaccine candidate is Glaxo […]

Continue Reading

Flu

Predicting Flu Evolution the Next Step Towards Better Flu Vaccines

Predicting Flu Evolution the Next Step Towards Better Flu Vaccines

Written by on November 21, 2014 in Antibodies, Flu with 0 Comments

Researchers discover that individual flu strains elicit an antibody response to multiple different flu strains already experienced by a patient A global team of researchers using a new modelling system have discovered that upon infection, patients exhibit immune responses to every strain that the individual has encountered, not just the infecting strain. The strongest responses […]

Continue Reading

Building a Universal Flu Vaccine

Building a Universal Flu Vaccine

Written by on October 23, 2014 in Featured on App, Features & Downloads, Flu with 0 Comments

Developing a universal flu vaccine requires a two part strategy targeted at the surface of the flu virus and it’s unchanging core At Last week’s World Vaccine Congress 2014, Vaccine Nation sat down with professor Sarah Gilbertson from the University of Oxford to discuss her progress towards developing a universal vaccine. What strategy are you […]

Continue Reading

Regulation & Policy

Is the WHO Blaming BigPharma for Ebola?

Is the WHO Blaming BigPharma for Ebola?

Written by on November 5, 2014 in Emerging Markets, News, Regulation and Policy with 1 Comment

No. They’re blaming governments for not investing. WHO Director General, Dr. Margaret Chan, said on Monday that the lack of an Ebola vaccine is due to Ebola historically being confined to poor ‘African nations. At the regional committee for Africa in Benin on Monday, Dr. Chan, Director general of the World Health Organization, said that […]

Continue Reading

Vaccines and Autism: Infographic

Vaccines and Autism: Infographic

Written by on September 23, 2014 in Featured on App, Regulation and Policy with 0 Comments

Source: Healthcare-management-degree.net

Continue Reading

Emerging Markets

Chikungunya Vaccine Succeeds in Phase I: Paving the way for a new generation of vaccines

Chikungunya Vaccine Succeeds in Phase I: Paving the way for a new generation of vaccines

Written by on November 21, 2014 in Emerging Markets with 1 Comment

Themis Bioscience and the Institut Pasteur announce positive chikungunya vaccine results in phase I using revolutionary measles vector Vienna-based Themis Bioscience, and the Paris based Institut Pasteur announced earlier this week a successful phase I trial of their revolutionary chikungunya vaccine. The phase 1 trial of 42 subjects demonstrated the vaccine to be well tolerated […]

Continue Reading

Reprieve for HIV Vaccines?

Reprieve for HIV Vaccines?

Written by on October 31, 2014 in Emerging Markets with 2 Comments

ALVAC-HIV and AIDSVAX resurected in promising South Africa Trial of the two HIV Vaccines A new trial of the ALVAC-HIV + AIDSVAX HIV vaccine regimen, conducted in South Africa, has demonstrated its safety and a robust immune response amongst 100 healthy adults. This trial, named HVTN 097, comes in the wake of the high-profile disappointment […]

Continue Reading

Supply Chain

Download The Need to Improve: Introducing Innovations in Existing Vaccine Processes

Download The Need to Improve: Introducing Innovations in Existing Vaccine Processes

Written by on November 16, 2014 in Supply Chain with 0 Comments

Ronald Neeleman, Sanofi Pasteur joined us last year at the World Vaccine Congress Europe to present on ‘THE NEED TO IMPROVE: Introducing Innovations in Existing Vaccine Processes’ Download this presentation now to find out more about: Large Companies are Optimized For Stability A turbulent World! Innovation Horizons Simulation of Manufacturing Logistics Anti-counterfeiting Principle of the […]

Continue Reading

The HPV Cancer Vaccine: Two Doses May Be Enough

The HPV Cancer Vaccine: Two Doses May Be Enough

Written by on August 28, 2014 in Featured on App, News, Prophylactic Vaccines, Supply Chain with 0 Comments

Studies have shown that two, instead of three doses, of the HPV vaccine may be enough to prevent the virus On Monday the 25th of August, the 29th International Papillomavirus Conference came to a close in Seattle, USA. Amongst the most hotly debated topics at the conference was lowering the number of doses of the […]

Continue Reading

Strategy and Partnering

Whistleblowers Reveal Merck Misrepresented Mumps Vaccine Efficacy

Whistleblowers Reveal Merck Misrepresented Mumps Vaccine Efficacy

Written by on September 10, 2014 in Featured on App, News, Partnering and Corporate strategy with 0 Comments

Two former Merck scientists have filed lawsuits against the company for misrepresenting efficacy results of its mumps vaccine Two former virologists for Merck have filed lawsuits against the company for misrepresenting efficacy results of its mumps vaccine. A US district judge from Pennsylvania, Darnell Jones II, has ruled that the pair of whistleblowers have provided […]

Continue Reading

Advaxis and Merck Partnership for Immunotherapy Prostate Cancer Drug Trial

Advaxis and Merck Partnership for Immunotherapy Prostate Cancer Drug Trial

Written by on September 4, 2014 in Featured on App, News, Partnering and Corporate strategy with 0 Comments

Advaxis and Merck have formed a partnership to conduct a clinical trial with their experimental prostate cancer drugs Advaxis and Merck have formed a partnership to test their experimental prostate cancer drugs, ADXS-PSA and anti PD-1 antibody pembrolizumab, to see if the combination of these two drugs will yield psoitive results in a phase I/II trial […]

Continue Reading

Other Recent Posts

Themis Bioscience’s Vaccine against Chikungunya Successful in Phase 1

Results presented at international conferences in Philadelphia and New Orleans November 20, 2014 The induction of neutralizing antibodies by a prophylactic Chikungunya vaccine candidate has now been confirmed by the final results of a phase 1 clinical trial, as well as its tolerability and safety. Detailed information of the trial has been presented at two […]

Continue Reading

NW Bio Announces financings Totalling $35 Million to Expand and Accelerate DCVax-L and DCVax-Direct Programs

Funding Includes $25 Million Equity Investment By Leading UK Investment Fundand $10 Million Mortgage Financing BETHESDA, Md., Nov. 19, 2014 /PRNewswire/ — Northwest Biotherapeutics (NASDAQ: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today two financings totaling $35 million.  The financings include a $25 million equity investment by […]

Continue Reading

Pfizer Forms Global Strategic Alliance with Merck KGaA, Germany, to Jointly Develop and Commercialize Anti-PD-L1 to Accelerate Presence in Immuno-Oncology

PD-L1 Antibody Clinical Results Consistent with Class; Interim Data Demonstrated A Complete and Partial Responses in Ovarian Cancer and NSCLC Up to 20 High Priority Immuno-Oncology Clinical Development Programs, Including Up to 6 Registration Trials, Expected to Commence in 2015 November 17, 2014 Pfizer Inc. announced today that it has entered into an agreement with […]

Continue Reading

Top
Geolocation